- Home
- EMF vs CLLS Comparison
EMF vs CLLS Comparison
Compare EMF & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- CLLS
- Stock Information
- Founded
- EMF 1987
- CLLS 1999
- Country
- EMF United States
- CLLS France
- Employees
- EMF N/A
- CLLS N/A
- Industry
- EMF Finance/Investors Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- CLLS Health Care
- Exchange
- EMF Nasdaq
- CLLS Nasdaq
- Market Cap
- EMF 219.3M
- CLLS 260.8M
- IPO Year
- EMF N/A
- CLLS 2007
- Fundamental
- Price
- EMF $15.48
- CLLS $2.85
- Analyst Decision
- EMF
- CLLS Buy
- Analyst Count
- EMF 0
- CLLS 1
- Target Price
- EMF N/A
- CLLS $4.00
- AVG Volume (30 Days)
- EMF 29.3K
- CLLS 285.2K
- Earning Date
- EMF 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- EMF 6.16%
- CLLS N/A
- EPS Growth
- EMF N/A
- CLLS N/A
- EPS
- EMF N/A
- CLLS N/A
- Revenue
- EMF N/A
- CLLS $63,438,000.00
- Revenue This Year
- EMF N/A
- CLLS N/A
- Revenue Next Year
- EMF N/A
- CLLS $4.90
- P/E Ratio
- EMF N/A
- CLLS N/A
- Revenue Growth
- EMF N/A
- CLLS 223.09
- 52 Week Low
- EMF $10.58
- CLLS $1.10
- 52 Week High
- EMF $12.67
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- EMF 67.87
- CLLS 62.05
- Support Level
- EMF $14.83
- CLLS $2.70
- Resistance Level
- EMF $15.54
- CLLS $2.81
- Average True Range (ATR)
- EMF 0.20
- CLLS 0.27
- MACD
- EMF 0.02
- CLLS -0.01
- Stochastic Oscillator
- EMF 95.83
- CLLS 51.85
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.